Personalized circulating tumor DNA for monitoring disease status in head and neck squamous cell carcinoma.
Glenn J HannaMichael J DennisNicole ScarfoMichelle S MullinRosh K V SethiKartik SehgalDonald J AnninoLaura A GoguenRobert I HaddadRoy B TishlerDanielle N MargalitRavindra UppaluriJonathan D SchoenfeldEleni M RettigPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Tumor-informed ctDNA testing is feasible in non-viral HNSCC. ctDNA positivity is an indicator of disease progression and associated with inferior survival. Further research is warranted to understand whether ctDNA may be leveraged to guide therapy in HNSCC.